Succinate pretreatment attenuates intestinal ischemia-reperfusion injury by inhibiting necroptosis and inflammation via upregulating Klf4
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110425 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Zhen Cao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China. Hauptthemen laut MEDLINE: Reperfusion Injury, Succinic Acid, Kruppel-Like Factor 4. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Intestinal ischemia-reperfusion (I/R) injury is a common pathophysiological process in various diseases, and the disruption of the intestinal barrier composed of tight junction proteins is the initiating factor, which then leads to a large number of bacteria and endotoxins in the intestine into the bloodstream causing stress and distant organ damage. The release of inflammatory mediators and abnormal programmed death of intestinal epithelial cells are important factors of intestinal barrier damage. Succinate is an intermediate product of the tricarboxylic acid cycle with anti-inflammatory and pro-angiogenic activities, but its role in the maintenance of intestinal barrier homeostasis after I/R has not been fully elucidated. In this study, we explored the effect of succinate on intestinal ischemia-reperfusion injury and the possible mechanism of its role by flow cytometry, western blotting, real-time quantitative PCR and immunostaining. The results of pretreatment with succinate in the mouse intestinal I/R model and IEC-6 cells hypoxia-reoxygenation (H/R) model revealed a reduction in tissue damage, necroptosis and associated inflammation due to ischemia-reperfusion. Furthermore, it was found that the protective effect of succinate pretreatment may be associated with the transcriptional upregulation of the inflammatory protein KLF4 and the protective effect of intestinal barrier of succinate was diminished after inhibition of KLF4. Thus, our results suggest that succinate can exert a protective effect in intestinal ischemia-reperfusion injury through upregulation of KLF4 and also demonstrate the potential therapeutic value of succinate pretreatment in acute I/R injury of the intestine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
- State Key Laboratory of Natural and Biomimetic Drugs; Department of Molecular and Cellular Pharmacology, Peking University School of Pharmaceutical Sciences, Beijing 100191, China.
- Department of General Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China. Electronic address: 694760993@qq.com.
- Department of General Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China. Electronic address: zcjdlyxzx@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Cao, Z., Mu, S., Wang, M., Zhang, Y., Zou, G., Yuan, X., Huang, Y., Yu, S., Zhang, J., & Zhang, C. (2023). Succinate pretreatment attenuates intestinal ischemia-reperfusion injury by inhibiting necroptosis and inflammation via upregulating Klf4. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110425
Vancouver
Cao Z, Mu S, Wang M, Zhang Y, Zou G, Yuan X, et al. Succinate pretreatment attenuates intestinal ischemia-reperfusion injury by inhibiting necroptosis and inflammation via upregulating Klf4. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110425
BibTeX
@article{Cao2023,
author = {Cao, Zhen and Mu, Silong and Wang, Maihuan and Zhang, Yun and Zou, Guijun and Yuan, Xinpu and Huang, Yun and Yu, Siwang and Zhang, Jinming and Zhang, Chaojun},
title = {Succinate pretreatment attenuates intestinal ischemia-reperfusion injury by inhibiting necroptosis and inflammation via upregulating Klf4},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110425}
}
EUVIMED